A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

PURPOSE: Clostridium difficile infection (CDI) represents a significant economic healthcare burden, especially the cost of recurrent disease. Fidaxomicin produced significantly lower recurrence rates and higher sustained cure rates in clinical trials. We evaluated the cost-effectiveness and budget i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Infection
Autori principali: Watt, Maureen, McCrea, Charles, Johal, Sukhvinder, Posnett, John, Nazir, Jameel
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2016
Soggetti:
Original Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5042976/
https://ncbi.nlm.nih.gov/pubmed/27062378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s15010-016-0894-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi